Leerink Partnrs Has Negative Estimate for IRWD Q4 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Equities researchers at Leerink Partnrs decreased their Q4 2024 earnings per share estimates for shares of Ironwood Pharmaceuticals in a research note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst F. Khurshid now expects that the biotechnology company will post earnings of $0.08 per share for the quarter, down from their previous estimate of $0.09. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.08 per share. Leerink Partnrs also issued estimates for Ironwood Pharmaceuticals' Q3 2025 earnings at $0.07 EPS, FY2025 earnings at $0.06 EPS and FY2026 earnings at $0.36 EPS.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its earnings results on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business had revenue of $91.60 million during the quarter, compared to analysts' expectations of $91.22 million. During the same period in the prior year, the company earned $0.12 earnings per share. The firm's quarterly revenue was down 19.4% compared to the same quarter last year.

Other equities research analysts have also recently issued reports about the company. JMP Securities cut their target price on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a "market outperform" rating on the stock in a research note on Thursday, January 30th. Craig Hallum decreased their price objective on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a "buy" rating for the company in a report on Wednesday, January 22nd. Finally, StockNews.com cut Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, November 12th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, Ironwood Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $10.67.

Ironwood Pharmaceuticals Stock Performance

Shares of Ironwood Pharmaceuticals stock traded up $0.09 during midday trading on Friday, hitting $2.19. The company had a trading volume of 1,542,776 shares, compared to its average volume of 2,320,844. Ironwood Pharmaceuticals has a 52-week low of $2.05 and a 52-week high of $15.70. The stock has a market capitalization of $349.67 million, a P/E ratio of -72.17 and a beta of 0.29. The company has a 50 day moving average of $3.86 and a 200 day moving average of $4.42.

Institutional Trading of Ironwood Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. KBC Group NV boosted its stake in Ironwood Pharmaceuticals by 59.3% in the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 3,198 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of Ironwood Pharmaceuticals by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,932 shares of the biotechnology company's stock worth $150,000 after acquiring an additional 3,209 shares during the last quarter. Creative Planning grew its stake in Ironwood Pharmaceuticals by 12.7% during the third quarter. Creative Planning now owns 42,151 shares of the biotechnology company's stock valued at $174,000 after acquiring an additional 4,749 shares in the last quarter. Quantinno Capital Management LP increased its holdings in Ironwood Pharmaceuticals by 40.0% in the 3rd quarter. Quantinno Capital Management LP now owns 19,191 shares of the biotechnology company's stock valued at $79,000 after acquiring an additional 5,482 shares during the last quarter. Finally, Everence Capital Management Inc. lifted its stake in Ironwood Pharmaceuticals by 36.3% in the 3rd quarter. Everence Capital Management Inc. now owns 27,850 shares of the biotechnology company's stock worth $115,000 after purchasing an additional 7,420 shares in the last quarter.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CFO Sravan Kumar Emany sold 11,001 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $4.08, for a total value of $44,884.08. Following the completion of the sale, the chief financial officer now owns 309,572 shares in the company, valued at approximately $1,263,053.76. This represents a 3.43 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 12.90% of the stock is owned by corporate insiders.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.